K. Jie

发表

Involving “authentic” cancer patients, their caregivers, and multidisciplinary professionals in a quality improvement trajectory in a hospital cancer pathway: a study protocol

A. Moser, M. Veenstra, I. Melchior, 2018, Journal of multidisciplinary healthcare.

Clinical impact of assessing thrombus age using magnetic resonance venography prior to catheter-directed thrombolysis

J. Wildberger, L. Tick, H. ten Cate, 2022, European Radiology.

Evaluation of the AutoDimer D-dimer assay for the exclusion of pulmonary embolism

P. Pattynama, F. Leebeek, M. Kruip, 2007, Thrombosis and Haemostasis.

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.

P. Sonneveld, M. Mohty, M. Béné, 2021, The Lancet. Oncology.

The pro- and anticoagulant role of blood-borne phagocytes in patients with acute coronary syndrome

J. Kragten, M. Leers, J. Keuren, 2013, Thrombosis and Haemostasis.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

P. Sonneveld, M. Béné, M. Vekemans, 2019, The Lancet.

Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosis

P. Pattynama, H. Janssen, F. Leebeek, 2008, Thrombosis and Haemostasis.

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

E. Vellenga, B. Biemond, A. A. van de Loosdrecht, 2011, British journal of haematology.

Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program

E. Vellenga, B. Biemond, G. Huls, 2011 .

Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).

M. Kersten, D. de Jong, F. d'Amore, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

M. Kersten, H. Goldschmidt, P. Sonneveld, 2014, Haematologica.

Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA

P. Sonneveld, M. Béné, P. Moreau, 2019, Clinical Lymphoma Myeloma and Leukemia.

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

P. Sonneveld, V. V. D. van der Velden, M. Mohty, 2021, Blood.

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.

P. Sonneveld, E. Vellenga, B. van der Holt, 2010, Blood.

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.

M. Kersten, P. Sonneveld, E. Vellenga, 2018, The Lancet. Haematology.

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study

P. Sonneveld, P. Moreau, T. Facon, 2021, Haematologica.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.

P. Sonneveld, P. Moreau, L. Frenzel, 2020, The Lancet. Haematology.

Improving the experience of older people with colorectal and breast cancer in patient‐centred cancer care pathways using experience‐based co‐design

A. Moser, M. Veenstra, K. Jie, 2021, Health expectations : an international journal of public participation in health care and health policy.

Stories of Lymphoma Survivors in Early Aftercare

A. Beurskens, A. Moser, T. van der Weijden, 2020, Cancer nursing.

Association of Successful Ultrasound-Accelerated Catheter-Directed Thrombolysis with Postthrombotic Syndrome: A Post Hoc Analysis of the CAVA Trial

L. Tick, H. ten Cate, A. T. ten Cate‐Hoek, 2020, Thrombosis and Haemostasis.

Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial.

L. Tick, H. ten Cate, A. T. ten Cate‐Hoek, 2019, The Lancet. Haematology.

Intermediate and nonclassical monocytes show heterogeneity in patients with different types of acute coronary syndrome

H. ten Cate, J. Kragten, R. Loeffen, 2017, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

A conversation approach based on shared goal-setting and shared decision-making for nurses in cancer aftercare: A developmental study.

A. Beurskens, T. van der Weijden, G. Bours, 2018, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

Increased expression of TF on monocytes, but decreased numbers of TF bearing microparticles in blood from patients with acute myocardial infarction

M. Leers, K. Jie, Jeffrey F. W. Keuren, 2009, European journal of haematology.

PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY

P. Sonneveld, P. Moreau, T. Facon, 2019, HemaSphere.

PS1377 IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT-ELIGIBLE PATIENTS TREATED WITH DARATUMUMAB, BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE: CASSIOPEIA STUDY

P. Sonneveld, P. Moreau, L. Frenzel, 2019, HemaSphere.

Atypical polyarthritis as a major manifestation of light chain disease

K. Jie, R. Peeters, M. Starmans, 2012, Annals of Hematology.

[Interstitial pneumonitis as an adverse effect of thalidomide].

J. Potjewijd, P. Voogt, K. Jie, 2009, Nederlands tijdschrift voor geneeskunde.

The pro- and anticoagulant role of blood-borne phagocytes in patients with acute coronary syndrome

J. Kragten, M. Leers, J. Keuren, 2013, Thrombosis and Haemostasis.

CAVA (Ultrasound‐Accelerated Catheter‐Directed Thrombolysis on Preventing Post‐Thrombotic Syndrome) Trial: Long‐Term Follow‐Up Results

L. Tick, C. Wittens, H. ten Cate, 2021, Journal of the American Heart Association.

E. Vellenga, B. Biemond, A. A. van de Loosdrecht, 2011, British journal of haematology.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

M. Vekemans, M. Macro, C. Touzeau, 2024, The Lancet Oncology.